COVID-19 Vaccination – A Ray of Hope!!

Jagriti Yadav¹, Pradeep Tangade², Ankita Jain³, Nimisha Kumari²

¹Postgraduate Student, Department of public health dentistry, Teerthanker Mahaveer Dental College & Research Centre, Moradabad, Uttar Pradesh, India
²Professor & H.O.D, Department of public health dentistry, Teerthanker Mahaveer Dental College & Research Centre, Moradabad, Uttar Pradesh, India
³Reader, Department of public health dentistry, Teerthanker Mahaveer Dental College & Research Centre, Moradabad, Uttar Pradesh, India

DOI: 10.36348/sjodr.2021.v06i07.003 | Received: 21.05.2021 | Accepted: 25.06.2021 | Published: 17.07.2021

*Corresponding author: Jagriti Yadav

Abstract

On January 16, 2021, Free vaccination against COVID-19 get the ball rolling in India and the government is expected to be the largest vaccination lay out in the world and pleading all of its citizens to be immunized. Four of the eight COVID-19 vaccines currently undergoing clinical trials in India were created there. Covishield (the Oxford–AstraZeneca vaccine) and Covaxin, a home-grown vaccine produced by Bharat Biotech, have been licenced for limited emergency use by India's medicines authority. Manufacturers in India have said that they will be able to meet the country's future COVID-19 vaccination needs.

Keywords: Covid 19, soothing vaccine.

INTRODUCTION

A novel coronavirus (nCoV) spillover event has arisen as a public health emergency of international significance, with its epicentre in Wuhan, People's Republic of China. This outbreak began in December 2019, and as of February 28, 2020, there have been 83,704 confirmed cases of new coronavirus disease 2019 (COVID-19) worldwide, with 2,859 deaths, for a case fatality rate of 33%. India, which has a sophisticated vaccine development programme, intends to manufacture COVID-19 vaccine domestically as well as distribute it to countries that cannot afford to acquire expensive vaccines from the West. Even though some of the final details aren't known in India, data from clinical trials of many vaccinations support their eligibility for emergency permission.

In India, candidates for the COVID-19 vaccine are being tested in clinical trials.

Oxford–AstraZeneca COVID-19 vaccine

A viral vector vaccine developed by the British University of Oxford, British-Swedish firm AstraZeneca, and the Coalition for Epidemic Preparedness Innovations and distributed under the brand names Vaxzevria and Covishield. Due to a tiny number of complaints of an uncommon blood clot condition, the Oxford–AstraZeneca vaccine has been permanently suspended in Denmark and Norway. Two days after receiving a vaccination, side symptoms were frequently observed. Participants were asked to fill out a survey about side effects, and 66% of them said they had experienced at least one symptom following vaccination. Tiredness (45%) was the most common, followed by myalgia (44%), fever (34%), headache (28%), local pain at the injection site (27%), and joint pain (12%) nausea (8%) and diarrhea (3%).

Pfizer–BioNTech COVID-19 vaccine

This vaccine, also known as Comirnaty, is an mRNA vaccine developed by BioNTech in Germany and Pfizer in the United States. Fosun Pharma distributes Comirnaty in mainland China, Hong Kong, and Macau.

The vaccine was the first COVID-19 vaccine to be approved for emergency use and the first to be cleared for routine use by a strict regulatory authority. The United Kingdom was the first country to sanction its usage in an emergency in December 2020.

COVID-19 is prevented by the Pfizer–BioNTech COVID-19 vaccine, which protects against infection with the SARS-CoV-2 virus. Severe allergic reaction is one of the side effects. Pain at the injection site (84.1 percent), fatigue (62.9 percent), headache (55.1 percent), muscle pain (38.3 percent), chills (31.9 percent), joint pain (23.6 percent), fever (14.2 percent), injection site swelling (10.5 percent), injection site redness (9.5 percent), nausea (1.1 percent), and malaise were all reported as adverse reactions in participants 16 and older in clinical studies. The COVID-19 vaccine from Pfizer BioNTech shows a 95 percent effectiveness against symptomatic SARS-CoV-2 infection.

Johnson & Johnson COVID-19 vaccine

Janssen Pharmaceutica (a Johnson & Johnson company) and Beth Israel Deaconess Medical Center have developed a viral vector vaccine. It's also known as COVID-19 Vaccine Janssen and Janssen COVID-19 Vaccine. Due to a possible link between the Johnson & Johnson vaccine and a rare blood clot problem, three countries, Denmark, Finland, and Norway, have stopped using it in favour of other vaccines. It is a single-dose vaccination, as opposed to two-dose COVID-19 vaccines like those made by Pfizer and Moderna. The Food and Drug Administration (FDA) Trust Source and the European Commission, on a recommendation from the European Medicines Agency (EMA), issued emergency and conditional authorization for the Johnson & Johnson vaccine for people aged 18 and up in early 2021. In 40 countries, the vaccine has been licenced for emergency use. Headaches • fever • exhaustion • muscular aches • nausea • discomfort, irritation, redness, and swelling at the injection site are all possible adverse effects.

Sinopharm-BBIBP

The China National Pharmaceutical Group (Sinopharm) and its Beijing Institute of Biological Products have developed BBIBP-CorV, an inactivated viral vaccine.

WHO The first and second doses should be separated by 3–4 weeks. The second dose does not need to be repeated if it is given fewer than three weeks after the first. If the second dose is not given within 4 weeks, it should be given as soon as feasible. Vaccination is one of the most significant medical breakthroughs in contemporary history. As the coronavirus disease 2019 (COVID-19) pandemic rages on, the development of an effective vaccine is critical to preventing further disease morbidity and mortality, as well as, ideally, limiting viral infection's global spread.

Moderna COVID-19 vaccine

- COVID-19 Vaccine is another name for this vaccine. Moderna is an mRNA vaccine developed by Moderna, the National Institute of Allergy and Infectious Diseases of the United States, the Biomedical Advanced Research and Development Authority of the United States, and the Coalition for Epidemic Preparedness Innovations. mRNA-1273 is a gene that is found in the human genome. ModernaTX, Inc. is the manufacturer. mRNA vaccine is a type of vaccine. The number of shots is two, and they are separated by 28 days. How it's Given: A shot to the upper arm muscle does not imply Eggs, preservatives, latex, and metals are all present. You should not obtain an mRNA COVID-19 vaccine if you have had a severe allergic reaction (anaphylaxis) or an acute allergic reaction, even if it was not severe, to any ingredient in an mRNA COVID-19 vaccine (such as polyethylene glycol).
  - Possible Negative Consequences. In the arm where the shot was fired: • Pain • Redness • Swelling
  - The rest of your body consists of: • Tiredness • Headache • Muscle aches • Chills • Fever • Nausea

Within a day or two of receiving the vaccine, these adverse effects appear. They're natural indicators that your body is preparing to defend itself, and they'll go away in a few days.

Sputnik V COVID-19 vaccine

The Russian Gamaleya Research Institute of Epidemiology and Microbiology developed a viral vector vaccine. Sputnik V uses two separate human adenoviruses, unlike Covishield, which uses a weakened common cold "adenovirus" that affects chimps. The first dosage of Sputnik V was provided in Hyderabad after receiving approval from the Central Drugs Laboratory, which conducted several testing on the vaccine's purity and stability.

Novavax protein based vaccine

Codename NVX-CoV2373, and also called SARS-CoV-2 rS (recombinant spike) protein nanoparticle with Matrix-M1 adjuvant, is a COVID-19 vaccine candidate developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI) and is undergoing trials in India under the brand name Covovax. It requires two doses and is stable at 2 to 8 °C (36 to 46 °F) refrigerated temperatures. Novavax plans on seeking authorization for the vaccine in the U.S., Europe, and other countries by the end of September 2021, with the goal of producing 100 million doses a month by then.

Sinovac/Coronavac inactivated virus type vaccine

Sinovac Biotech, a Chinese business, has created an inactivated viral COVID-19 vaccine. It was tested in Phase III clinical trials in Brazil, Chile, Indonesia, the Philippines, and Turkey, and it uses classic technology comparable to BBIBP-CorV and Covaxin, two other COVID-19 inactivated-virus vaccines. CoronaVac does not require freezing, and both the finished product and the raw material used to make CoronaVac can be delivered chilled at 2–8 °C (36–46 °F), the same temperature as flu vaccines.
REFERENCES


- Johns Hopkins University Coronavirus Resource Center. COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University, 2020 (https://coronavirus.jhu.edu/map.html. opens in new tab)


superior nonimmunogenic vector with increased translational capacity and biological stability. Molecular therapy, 16(11), 1833-1840.


